Although the sample size is small, these findings support the clinical benefit of zanidatamab treatment for HER2-positive SGC.
Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients With Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase Studies
Keun-Wook Lee·Funda Meric-Bernstam·Do-Youn Oh·Muralidhar Beeram·Toshihiko Doi·Kay T. Yeung·T. Samuel Nached·Kavita Shah·Douglas S. Fuller·Diana Shpektor·Emanuele Loro·Elena Elimova